The CEOs of eight multinational companies were replaced

of which 70% were Koreans.

Conversion of the domestic system such as Galderma and Merck

CEOs of new subsidiaries such as Viatris and Organon are also confirmed

From the top left, CEOs of Oh Dong-wook, Kim Youn-hee, Choi Ho-jin, Kim So-eun, Kim Woo-gyu, Lee Hye-young, Kevin Peters, and Rob Kempton

Eight multinational pharmaceutical companies have appointed new CEOs during this year On the 14th, Dailypharm collected the current status of CEOs of major multinational companies in Korea, including 31 Korea Global Pharmaceutical Industry Associations (KRPIA) (currently).

 

As a result, 8 pharmaceutical companies replaced or appointed new CEOs.

 

Although there were regular personnel executions due to the expiration of the term, there were also personnel measures due to separate issues such as merger and corporate division.

 

The foreign head of the three pharmaceutical companies left.

 

The KRPIA is represented by Dong-wook Oh, President of Pfizer Korea, instead of Avi BenShoshan, former CEO of MSD Korea.

 

As of October, Galderma Korea appointed CEO Kim Youn-hee and changed the system to a Korean president again in about two years after Park Heung-beom resigned.

 

Rene Wipperich, former CEO of Galderma Korea for two years from September 2018, moved to a Swiss subsidiary.

 

Current status of CEOs of major multinational pharmaceutical companies

Merck, which has maintained a foreign system since the inauguration of the Korean subsidiary, appointed Kim Woo-gyu in September.

 

He received his Ph.D from the University of Delaware in the United States and was appointed as a Korean subsidiary after serving as the head of the Performance Materials division at the German headquarters of the Merck Group in 1997.

 

Ono Pharma Korea, which has been replaced in about a year, continues the Korean system by appointing former Vice President Choi Ho-jin as CEO along with the retirement of former CEO Min-yeol Yang.

 

Ono Pharma Korea was managed by former CEO Takashi Kishi, who was appointed former CEO Yang.

 

There is also news of the appointment of the head of a new corporation to be launched due to the division of the corporation.

 

Viatris, which had been maintained under the name of Pfizer Upjohn, which was created through the corporate division of Pfizer, was officially launched and appointed Lee Hye-young as the first CEO.

 

CEO Lee was in charge of Pfizer's patent expiration division.

 

In the case of MSD, the official term of office began next year and was not reflected in the count, but Organon, which is spun off from MSD, was also appointed by Kim So-eun as the head of the first Korean subsidiary.

 

Executive Director Kim will lead Organon from February next year.

 

MSD and GSK's Korean subsidiaries continue to be foreign CEOs.

 

MSD appoints Kevin Peters from a Thai subsidiary, and GSK's new president, Rob Kempton, takes over as Julien Samson moves to the headquarters.

 

Mundipharma appointed Choi Heon and Astellas appointed Weber Markus as the new president.

 

The proportion of Koreans among CEOs of multinational companies was 70%, a slight increase from the previous year (66%).

 

In addition, the proportion of female CEOs fell 5% to 25%.